Caspofungin: an overview

References

• Denning DW. Echinocandins and pneumocandins – a new antifungal class with a novel mode of action. J. Microb. Chemother. 40, 611–614 (1997).
   PubMed Web of Science ®Google Scholar
• Nyfeler R, Keller SW. Metabolites of microorganisms, 143: echinocandin B, a novel polypeptide antibiotic from Aspergillus nidulans var. echinulatus-isolation and structural components. Helv. Chim. Acta 57, 2459–2477 (1974).
   PubMed Web of Science ®Google Scholar
• Masurekar PS, Fountoulakis JM, Hallada TC et al. Pneumocandins from Zalerion arboricola, II: modification of product spectrum by mutation and medium manipulation. J. Antibiot. 45, 1867–1874 (1992).
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Fujie A, Sakamoto K et al. WF11899A, B and C, novel antifungal lipopeptides, I: taxonomy, fermentation, isolation, and physico-chemical properties. J. Antibiot. 47, 1084–1091 (1994).
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Lambros M, Johnson D. Aerosolization potential of caspofungin (CAS). Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Odds FC, Motyl M, Andrade R et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42, 3475–3482 (2004).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Survelillance Program conducted in 2001 and 2002. J. Clin. Microbiol. 42, 3142–3146 (2004).
   PubMed Web of Science ®Google Scholar
• Marco F, Pfaller MA, Messer SA et al. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 31, 33–37 (1998).
   Web of Science ®Google Scholar
• Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41, 2326–2332 (1997).
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Schimizzi AM, Fothergill AW et al. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 18, 302–304 (1999).
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Klepser ME, Ernst ME et al. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis. 33, 75–80 (1999).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36, 2950–2956 (1998).
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Lynch M, Biokov D et al. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41, 1612–1614 (1997).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Jones RN, Doern GV et al. International surveillance of blood stream infections due to Candida species in European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis. 35, 19–25 (1999).
   PubMed Web of Science ®Google Scholar
• Krishnarao TV, Galgiani JN. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41, 1957–1960 (1997).
   PubMed Web of Science ®Google Scholar
• Flattery AM, Hicks PS, Wilcox A et al. In vitro susceptibility of clinical trial isolates of Aspergillus spp. to the echinocandin antifungal caspofungin (Cancidas™, MK-0991). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Ontario, Canada, 936 (2000).
   Google Scholar
• Simmons EJ, Abruzzo G, Bowman J et al. Activity of caspofungin acetate against Aspergillus flavus, Asperillus terreus, and Aspergillus nidulans. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Chiller T, Farrokhshad K, Brummer E et al. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 39, 99–103 (2001).
   PubMed Web of Science ®Google Scholar
• Chiller T, Farrokhshad K, Brummer E et al. Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob. Agents Chemother. 44, 3302–3305 (2000).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Marco F, Messer SA et al. In vitro activity of two echinocandin derivatives, LY202255 and MK-0991 (L-473,792) against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30, 251–255 (1998).
   PubMed Web of Science ®Google Scholar
• Motyl MR, Nielsen Kahn J, Giacobbe RA. In vitro susceptibility of dermatophytes to CANCIDAS (caspofungin acetate). Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Edlind TD, Katiyar SK. Caspofungin-tolerant mutants of Candida albicans and Candida glabrata. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Osherov N, May GS, Albert ND et al. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 46, 2462–2469 (2002).
   PubMed Web of Science ®Google Scholar
• Schuetzer-Muehlbauer M, Willinger B, Krapf G et al. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Molec. Microbiol. 48, 225–235 (2003).
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Groll AH et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46, 12–23 (2002).
   PubMed Web of Science ®Google Scholar
• Graybill JR, Najvar LK, Montalbo EM et al. Treatment of histoplasmosis with MK-0991 (L-743,872). Antimicrob. Agents Chemother. 42, 151–153 (1998).
   PubMed Web of Science ®Google Scholar
• Graybill JR, Bocanegra R, Luther M et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob. Agents Chemother. 41, 1937–1939 (1997).
   PubMed Web of Science ®Google Scholar
• Kohler S, Wheat LJ, Connolly P et al. Comparison of the echinocandin casofungin with amphotericin B for the treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. 44, 1850–1854 (2000).
   PubMed Web of Science ®Google Scholar
• Gonzalez GM, Najyar LK, Tijerina R et al. Therapeutic efficacy of caspofungin (CAS) alone or in combination with amphotericin B (DAMB) or liposomal amphotericin B (LAMB) for coccidioidomycosis in a mouse model. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Ibrahim AS, Bowman JC, Avanessian V et al. Efficacy of caspofungin acetate (CAS) in a diabetic murine model of induced mucromycosis. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Bocanegra R, Najvar LK, Hernandez S et al. Novel antifungal agents in murine scedosporiosis. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Powles MA, Liberator P, Anderson J et al. Efficiacy of MK-0991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother. 42, 1985–1989 (1998).
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 362, 1142–1151 (2003).
   PubMed Web of Science ®Google Scholar
• Cancidas® (caspofungin acetate) prescribing information. Merck & Co., NJ, USA.
   Google Scholar
• Stone JA, Li S, Winchell S et al. Population pharmocokinetics of caspofungin in candidiasis patients. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, A-1571 (2003).
   Google Scholar
• Odio CM, Araya R, Pinto LE et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. 23, 1093–1097 (2004).
   PubMed Web of Science ®Google Scholar
• Hesseling M, Weindling M, Neal T. First reported use of caspofungin in an extremely low-birth-weight neonate. J. Matern. Fetal Neonatal Med. 14, 212 (2003).
   PubMedGoogle Scholar
• Stone JA, Holland SD, Wickersham PJ et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46, 739–745 (2002).
   PubMed Web of Science ®Google Scholar
• Hajdu R, Thompson R, Sundelof JG et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41, 2339–2344 (1997).
   PubMed Web of Science ®Google Scholar
• Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant. 34, 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Hachem R, Papanicolaou G et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transplant. Infect. Dis. 6, 110–116 (2004).
   PubMedGoogle Scholar
• Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized, double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33, 1529–1535 (2001).
   PubMed Web of Science ®Google Scholar
• Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113, 294–299 (2002).
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C et al., Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347, 2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• Karsonis NA, Saah A, Lipka CJ et al. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J. Antimicrob. Chemother. 53, 878–881 (2004).
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Sable CA et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations, or azoles. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Ontario, Canada, 1103 (2000).
   Google Scholar
• Kartsonis N, Saah A, Lipka J et al. Salvage therapy (Rx) with caspofungin (CAS) for invasive aspergillosis (IA): results from the CAS compassionate use (CU) study. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatent of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39, 1563–1571 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351, 1391–1402.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Kantarjian H, Alvarado G et al. Intravenous itraconazole (ITRA) vs caspofungin (CASPO) prophylaxis (P) in patients (PTS) with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC). Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis. 37, S188–S224 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson MD, MacDougall C, Ostrosky-Zeichner L et al. Combination antifungal therapy. Antimicrob. Agents Chemother. 48, 693–715 (2004).
   PubMed Web of Science ®Google Scholar
• Roling EE, Klepser ME, Wasson A et al. Antufungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida species and Cryptococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis. 43, 13–17 (2002).
   PubMed Web of Science ®Google Scholar
• Gil Lamaignere C, Muller FMC. Differential effects of the combination of caspofungin with terbinafine against C. dubliniensis and C. kefyr. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Perea S, Gonzalez G, Fothergill AW et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus species. Antimicrob. Agents Chemother. 46, 3039–3041 (2002).
   PubMed Web of Science ®Google Scholar
• Kohno S, Maesaki S, Iwakawa J et al. Synergistic effects of combination of FK463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Ontario, Canada, 1686 (2000).
   Google Scholar
• Nakajima M, Tamada S, Toshida K et al. Pathological findings in a murine pulmonary aspergillosis model: treatment with FK463, amphotericin B and a combination of FK463 and amphotericin B. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Ontario, Canada, 1685 (2000).
   Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46, 245–247 (2002).
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G et al. Combined activity in vitro of caspofungin plus amphotericin B or plus azole agents against itraconazole resistant clinical isolates of Aspergillus fumigatus. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Sabatelli F. In vitro and in vivo interaction of posaconazole (POS) and caspofungin (CSP) against Aspergillus. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Warn PA, Sharp A, Morrissey G et al. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J. Antimicrob. Chemother. 50, 1071–1074 (2002).
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187, 1834–1843 (2003).
   PubMed Web of Science ®Google Scholar
• Wheat LJ. Combination therapy for aspergillosis: is it needed, and which combination? J. Infect. Dis. 187, 1831–1833 (2003).
   PubMed Web of Science ®Google Scholar
• Sabatelli F. In vitro and in vivo interaction of posaconazole (POS) and caspofungin (CSP) against Aspergillus. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
   Google Scholar
• Marr K. Combination antifungal therapy: where are we now, and where are we going? Oncology 18(Suppl. 7), 24–29 (2004).
   PubMedGoogle Scholar
• Aliff TB, Maslak PG, Jurcic JG et al. Refractory Aspergillus pneumonia in patients with acute leukemia – successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97, 1025–1032 (2003).
   PubMed Web of Science ®Google Scholar
• Thiebaut A Sr, Antal D, Breysse MC et al. Refractory invasive fungal infections in patients with hematologic malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002).
   Google Scholar
• Castagnola E, Machetti M, Cappelli B et al. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant. Clin. Microbiol. Infect. 10(3), 255–257 (2004).
   PubMed Web of Science ®Google Scholar
• Hubel K, Chemnitz J, Brochhagen HG. Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia. Int. J. Hemat. 79, 289–292 (2004).
   PubMed Web of Science ®Google Scholar
• Wertz KK, Pretzlaff RK. Caspofungin in a pediatric patient with persistent candidemia. Ped. Crit. Care Med. 5, 181–183 (2004).
   PubMedGoogle Scholar
• Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98, 292–299 (2003).
   PubMed Web of Science ®Google Scholar
• Gentina T, De Botton S, Alfandari S et al. Combination antifungals for treatment of pulmonary invasive aspergillosis (IA) refractory to amphotericin B (AmB) in leukaemia patients. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002).
   Google Scholar
• Steinbach WJ, Schell WA, Miller JL et al. Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of scopulariopsis infections in immunocompromised patients. J. Infect. 48, 112–116 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA et al. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39, 797–802 (2004).
   PubMed Web of Science ®Google Scholar
• Cesaro S, Toffolutti T, Messina C et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur. J. Haematol. 73, 50–55 (2004).
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R et al. Multicenter noncomparative study of caspofungin (CAS) combined with other antifungals in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to standard regimens. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2004).
   Google Scholar
• Viscoli C. Combination therapy for invasive aspergillosis. Clin. Infect. Dis. 39, 803–805 (2004).
   PubMed Web of Science ®Google Scholar
• Cesaro S, Visintin G. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 40, 1073–1075 (2005).
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Kim HW. Reply to Cesaro and Visintin. Clin. Infect. Dis. 40(7), 1075–1076 (2005).
   Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408–415 (2002).
   PubMed Web of Science ®Google Scholar